Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609708 | 0.80 | RIPK1 (0.57) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL13715906 | 0.79 | TAAR1 (0.58) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| SCHEMBL3672929 | 0.78 | TRPA1 (0.67) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| SCHEMBL6280516 | 0.78 | RIPK1 (0.67) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL3674520 | 0.77 | TRPA1 (0.59) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| SCHEMBL136376 | 0.76 | TAAR1 (0.61) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| SCHEMBL4443642 | 0.76 | TAAR1 (0.61) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| Benzene SCHEMBL5290987 | 0.76 | TAAR1 (0.61) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| SCHEMBL17453236 | 0.76 | TAAR1 (0.61) | TAAR1AOC3TRPA1RIPK1ALDH1A1 | |
| Lithium SCHEMBL30777534 | 0.76 | RIPK1 (0.64) | TAAR1AOC3TRPA1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117205-A1 | BICYCLIC PYRIDINE DERIVATIVE AND SALT THEREOF, AND HARMFUL ORGANISM CONTROL AGENT CHARACTERIZED BY CONTAINING SAID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 北興化学工業株式会社 | 2024-06-06 | — | — | WO | disclosed |
| WO-2018193463-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TETRAHYDROISOQUINOLINE COMPOUNDS | NEON LABORATORIES LIMITED (IN) | 2018-10-25 | — | — | WO | disclosed |
| US-7902179-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1375489-B1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1219612-B1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | HANASAKI KOJI | 2007-04-19 | — | — | US | disclosed |
| US-4826992-A | MICROBIOCIDE INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| US-4795815-A | BACTERICIDES, MICROBIOCIDES | ELI LILLY AND COMPANY (US) | 1989-01-03 | — | — | US | disclosed |
| US-4734504-A | 1-alkylated diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4734505-A | 1-(alkylated)-2-(acylated)diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4716232-A | 1-(vinyl phosphonate adduct) pyrazolidinones | ELI LILLY AND COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0203723-A1 | 2,3-(dihydro)bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0104432-A2 | Herbicide and plant growth regulator comprising alpha-beta-unsaturated compound | TEIJIN LIMITED (JP) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | TAAR1 203/4885AOC3 3019/4885TRPA1 24/4885 |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | TAAR1 99/4885AOC3 2744/4885TRPA1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.